NON-SMALL CELL LUNG CANCER

This study tests a new drug called LY4052031 in people with advanced or metastatic solid tumors, including bladder, breast, lung, and other cancers. The drug is designed to target and attack cancer cells while sparing healthy ones. The trial has two parts: first to find the safes…

This early-phase study tests a new drug called 177Lu-RAD204 in people with advanced solid tumors (like lung, breast, or skin cancer) that have not responded to other treatments. The drug delivers a small amount of radiation directly to cancer cells by targeting a protein called P…

This study tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-squamous lung cancer whose tumors have PD-L1 levels of 1% or higher…

This study tests whether a new drug called ivonescimab, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has spread. About 1,600 adults with stage IV lung c…

This study tests whether adding high-dose radiation to standard drug therapy (chemotherapy or immunotherapy) improves survival in people with non-small cell lung cancer that has spread to up to 5 spots. About 240 participants will be randomly assigned to receive either standard t…

This early-phase study tests a new drug called GNC-077 in about 20 adults with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the …

This study tests an experimental drug, STX-721, in people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2 exon 20 insertions). The goal is to find a safe dose and see if it can shrink tumors. About 251 adults whose cancer has spread or can…

This study tests a daily pill called pyrotinib for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene. The goal is to see if the drug can shrink tumors and control the disease as a first treatment. About 18 adults who have not had prior th…

This study tests whether a new drug called rilvegostomig, when added to standard chemotherapy, helps people with advanced squamous non-small cell lung cancer live longer or delay cancer growth. It is for people whose tumors have a specific protein (PD-L1). About 880 participants …

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink or control the cancer. About 350 participants with various cancer types will take part in thi…

This study is testing two different dosing schedules for a new, injectable form of an immunotherapy drug (nivolumab) when given with another immunotherapy (ipilimumab) and standard chemotherapy. It aims to see how the body processes the drugs and how safe they are for people with…

This study tests an experimental drug called TQB2102 for people with advanced non-small cell lung cancer that has a HER2 gene abnormality. The drug is designed to deliver a strong cancer-killing agent directly to tumor cells while sparing healthy tissue. About 270 adults aged 18-…

This study tests two drugs, GEN-725 and dositinib, together in people with advanced lung cancer that has a specific gene change (EGFR mutation). The goal is to see if the combination is safe and can shrink tumors or slow the cancer's growth. About 110 adults aged 18-75 are taking…

This early-phase study tests a new drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have not responded to at least two prior treatments. The main goals are to check the drug's safety and find the best dose. About 96 participa…

This study tests an experimental drug that delivers radiation directly to cancer cells by targeting a protein called Nectin-4. It is for people with advanced solid tumors (like bladder, breast, lung, or cervical cancer) that have not responded to prior treatments. The goal is to …

This study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check the drug's safety and find the best dose, often given with other cancer treatments. About 387 ad…

This early-phase study tests a new treatment for people with advanced lung cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goal is to find out if the trea…

This study is testing whether a lower dose of the targeted cancer drug osimertinib can safely control advanced EGFR-positive non-small cell lung cancer. About 58 adults whose cancer has not responded to surgery or radiation will take 80 mg every other day. Researchers will monito…

This study tests a new drug called SHR-A2102 combined with other cancer treatments for people with a type of lung cancer that can be removed with surgery. The goal is to see if the combination helps shrink or eliminate the cancer before surgery and prevents it from coming back af…

This study tests whether combining a targeted drug (adagrasib) with precise radiation (SRS) can better control brain tumors in people with a specific type of lung cancer (KRAS G12C mutation). About 30 adults with untreated brain metastases will receive both treatments. The goal i…

This study tests whether combining an immunotherapy drug (atezolizumab), an immune booster (BDB001), and targeted radiation can help control advanced solid tumors. About 247 adults with cancers like pancreatic, lung, or breast cancer will receive the treatment. The goal is to see…

This study tests a new drug called dositinib for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The goal is to find the safest dose and see if it can shrink tumors. About 153 adults aged 18-75 who have already tried other treat…

This study tests two experimental drugs, BNT326 and BNT327, together in people with advanced non-small cell lung cancer that has spread or come back. The goal is to find the best dose and see if the combination can shrink tumors. About 420 adults will take part, including those w…

This program provides early access to the investigational drug zidesamtinib for people with advanced ROS1-positive non-small cell lung cancer or other solid tumors who have run out of standard options and cannot join a clinical trial. Participants must have tried at least one pri…

This study looks at whether giving radiation therapy after surgery can help people with stage III non-small cell lung cancer who still have cancer cells after chemo-immunotherapy and surgery. About 118 adults will be randomly assigned to receive or not receive radiation to the ly…

This study tests whether adding nitroglycerin patches to standard radiation therapy improves outcomes for people with advanced lung cancer (with a specific EGFR gene change) that has spread to the brain. About 74 participants will receive either radiation alone or radiation plus …

This phase 3 trial tests whether a new drug called RC148, combined with chemotherapy, works better than the standard immunotherapy tislelizumab plus chemotherapy for people with advanced squamous non-small cell lung cancer who haven't had treatment before. About 574 adults aged 1…

This study tests an experimental oral drug called 7HP349 (Alintegimod) combined with standard immunotherapy drugs (ipilimumab and nivolumab) in adults with advanced solid tumors like melanoma, lung, kidney, or liver cancer that have not responded to prior treatments. The goal is …

This study tests a new way to deliver radiation for early-stage lung cancer or small lung tumors that have spread from other cancers. Instead of adding a safety margin around the tumor, doctors will use real-time imaging to target only the tumor itself. The goal is to see if this…

This early-phase study tests an oral drug called S241656 in adults with advanced cancers that have specific genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrin…

This study tests whether adding a third drug to standard immunotherapy (cemiplimab) plus chemotherapy helps shrink early-stage non-small cell lung cancer more before surgery. About 120 adults with stage II-IIIB lung cancer that can be removed will be randomly assigned to one of t…

This study tests a drug called zanidatamab in adults whose cancers have a specific change in the HER2 gene. It includes people with lung, colorectal, endometrial, head and neck, or sarcoma cancers that have not responded to other treatments. The main goal is to see if the drug ca…

This study compares two treatments for early-stage non-small cell lung cancer in patients who are at high risk for surgery. One group will have a small part of the lung removed (sublobar resection), and the other will receive targeted radiation (stereotactic ablative radiotherapy…

This study tests an experimental drug called VMD-928, taken as a pill, either alone or with pembrolizumab (an immunotherapy). It is for adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find the safest dose and see i…

This study tests a targeted pill (lazertinib) given alone or with chemotherapy before surgery for people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer). The goal is to see if these treatments can shrink tumors and improve surgical outcomes. About 16…

This study is testing a new type of PET scan that uses a special probe called 68Ga-TOI-1 to find and stage lung cancer. The probe targets a protein (CDH3) found only on cancer cells, which may make the scan more precise than current methods. About 80 adults with suspected or conf…

This study looks at whether a gentle exercise program is practical and helpful for people with lung cancer who are getting radiation therapy, along with their family caregivers. About 40 pairs (patient plus caregiver) will take part. The goal is to see if the program improves qua…

This study looks at whether a natural supplement called urolithin A can improve how the immune system responds to cancer immunotherapy. About 45 adults with newly diagnosed solid tumors (like lung cancer or melanoma) will receive either urolithin A or a placebo alongside their st…

This study is for Black patients with advanced non-small cell lung cancer who have not had treatment yet. It tests how well the drug pembrolizumab, with or without chemotherapy, works in real-world settings. Researchers will also look for biomarkers in the blood that might predic…

This study uses surveys to find out what factors are most important to Chinese patients and doctors when choosing the first targeted therapy for advanced non-small cell lung cancer. About 590 participants (patients and physicians) will share their preferences through a special qu…

This study looks at whether a lab-grown model made from a patient's own lung cancer cells can help doctors choose the most effective drugs. Researchers will compare the model's predictions to how the patient actually responds to treatment. About 250 adults with non-small cell lun…

This study is testing whether an artificial intelligence (AI) tool can help connect cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers and use the AI to suggest trials based on their tumor's genetic markers. The goal i…